The pairing the longevity world won’t stop talking about. Studied for the body’s own growth-hormone rhythms.
CJC-1295 and Ipamorelin are studied together for their complementary mechanisms of action on the somatotropic axis. CJC-1295 is a GHRH analog that may prolong pituitary stimulation via GRF receptor binding, while Ipamorelin acts as a selective ghrelin receptor agonist to support pulsatile growth hormone release. Research suggests this combination may engage IGF-1 related pathways, which are associated with protein synthesis, metabolic regulation, and cellular repair processes. Intended for research purposes.


CJC-1295 and Ipamorelin are studied together for their complementary action on the body’s own growth-hormone rhythm. CJC-1295 prolongs pituitary stimulation as a GHRH analog, while Ipamorelin selectively triggers pulsatile GH release — together supporting the IGF-1 pathway tied to protein synthesis, metabolic regulation, and cellular repair.
Research Use Only. These products have not been evaluated or approved by the FDA for use as drugs, therapeutics, diagnostics, or dietary supplements, and are not intended for administration to humans or animals. No product description or mechanism-of-action information constitutes a health claim or therapeutic endorsement. Any clinical use is at the sole discretion of a licensed healthcare provider in compliance with applicable laws. Individual results may vary.